Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 12;36(27):e197.
doi: 10.3346/jkms.2021.36.e197.

Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine

Kyungmin Huh #  1 , Yewon Na #  2   3 , Young Eun Kim #  4 , Munkhzul Radnaabaatar  2 , Kyong Ran Peck  5 , Jaehun Jung  2   6
Affiliations

Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine

Kyungmin Huh et al. J Korean Med Sci. .

Abstract

We used the nationwide claims database to calculate the incidence of thrombotic events and predict their overall 2-week incidence. From 2006 to 2020, the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) tended to increase. Unlike intracranial venous thrombosis (ICVT) and intracranial thrombophlebitis (ICTP), which showed no age difference, other venous embolism, and thrombosis (OVET), DIC, DVT, and PE were significantly more common in over 65 years. The overall 2-week incidence of ICVT was 0.21/1,000,000 (95% confidence interval [CI], 0.11-0.32). ICTP, OVET, DIC, DVT and PE were expected to occur in 0.08 (95% CI, 0.02-0.14), 7.66 (95% CI, 6.08-9.23), 5.95 (95% CI, 4.88-7.03), 13.28 (95% CI, 11.92-14.64), 14.09 (95% CI, 12.80-15.37) per 1,000,000, respectively. To date, of 8,548,231 patients vaccinated with ChAdOx1 nCoV-19 in Korea, two had confirmed thrombosis with thrombocytopenia syndrome within 2 weeks. The observed incidence of ICVT after vaccination was 0.23/1,000,000.

Keywords: COVID-19; Thrombosis with Thrombocytopenia Syndrome; Vaccination; Vaccine Adverse Events.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1. Observed and predicted incidences of the study conditions. (A) DVT; (B) ICVT; (C) ICTP; (D) PE; (E) OVET; (F) DIC.
DIC = disseminated intravascular coagulation, DVT = deep vein thrombosis, ICTP = intracranial thrombophlebitis, ICVT = intracranial venous thrombosis, PE = pulmonary embolism, OVET = other venous embolism, and thrombosis.
See this image and copyright information in PMC

References

    1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. - PMC - PubMed
    1. Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 2021;121:102663. - PMC - PubMed
    1. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964–1965. - PMC - PubMed
    1. Yocum A, Simon EL. Thrombotic thrombocytopenic purpura after Ad26.COV2-S vaccination. Am J Emerg Med. Forthcoming 2021. DOI: 10.1016/j.ajem.2021.05.001. - PMC - PubMed
    1. European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. [Updated 2021]. [Accessed May 31, 2021]. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-find....

MeSH terms